A Study of HRS-7535 Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequately Controlled With Metformin

Inclusion Criteria:

1. Male or female, 18-75 age years, both inclusive;

2. Type 2 diabetes mellitus diagnosed for at least 3 months before the screening visit;

3. HbA1c 7.5-11.0% (both inclusive) at screening;

4. Treated with conventional lifestyle intervention and stable treatment with metformin (≥1500 mg/day) at least 8 weeks prior to screening.

Exclusion Criteria:

1. Known or suspected allergy to the investigational drug or its components orexcipients.

2. Diagnosed or suspected with type 1 diabetes mellitus, special types of diabetes orsecondary diabetes.

3. Have a history of acute complications of diabetes (diabetic ketoacidosis, lacticacidosis, hyperglycaemic hyperosmolar state, etc.) within 6 months prior toscreening.

4. Proliferative retinopathy, maculopathy, painful diabetic neuropathy, diabetic footulcer or intermittent claudication requiring acute treatment;

5. Pregnancy, breast-feeding, intention of becoming pregnant during the trial; or womenof childbearing potential (WOCBP) or male subject not using adequate contraceptivemeasures.